Go offline with the Player FM app!
#178 - Orexin Agonists Are Here: This Is The New Stuff
Manage episode 519834077 series 3365942
The orexin receptor agonists are coming. After years of managing narcolepsy with stimulants, sodium oxybate, and wake-promoting agents, we soon will have medications that target the root cause of the disorder: the loss of orexin signaling. These new drugs—developed by Takeda, Alkermes, and Centessa—aren’t just incremental improvements. They represent a genuine shift in how we understand and treat hypersomnolence disorders. In this episode, we will:
- Define what orexin is and why losing it destabilizes wakefulness, REM boundaries, muscle tone, and cognition
- Learn how orexin agonists work—not as stimulants, but as replacement therapy for a missing neurotransmitter
- Find out why OX2R is the key receptor, and how selective agonists restore stable wakefulness, reduce cataplexy, and normalize attention
- Review the available clinical data from the new wave of programs: oveporexton (Takeda), alixorexton (Alkermes), and ORX750 (Centessa)
- See what makes these drugs different from modafinil, amphetamines, solriamfetol, and oxybate therapies
- Learn why Phase 1, Phase 2, and Phase 3 trials matter—with quick insights on how these drugs reached such strong results
- Consider safety and side effects, including what Hy’s Law means and why regulators watch liver signals so closely
- Look ahead to what these medications may mean for NT1, NT2, IH, and other hypersomnolence disorders in the coming years
- Speculate why this class represents one of the most exciting moments in modern sleep medicine
Produced by: Maeve Winter
More
- Twitter: @drchriswinter
- IG: @drchriwinter
- Threads: @drchriswinter
- Bluesky: @drchriswinter
- The Sleep Solution and The Rested Child
Thanks for listening and sleep well!
179 episodes
Manage episode 519834077 series 3365942
The orexin receptor agonists are coming. After years of managing narcolepsy with stimulants, sodium oxybate, and wake-promoting agents, we soon will have medications that target the root cause of the disorder: the loss of orexin signaling. These new drugs—developed by Takeda, Alkermes, and Centessa—aren’t just incremental improvements. They represent a genuine shift in how we understand and treat hypersomnolence disorders. In this episode, we will:
- Define what orexin is and why losing it destabilizes wakefulness, REM boundaries, muscle tone, and cognition
- Learn how orexin agonists work—not as stimulants, but as replacement therapy for a missing neurotransmitter
- Find out why OX2R is the key receptor, and how selective agonists restore stable wakefulness, reduce cataplexy, and normalize attention
- Review the available clinical data from the new wave of programs: oveporexton (Takeda), alixorexton (Alkermes), and ORX750 (Centessa)
- See what makes these drugs different from modafinil, amphetamines, solriamfetol, and oxybate therapies
- Learn why Phase 1, Phase 2, and Phase 3 trials matter—with quick insights on how these drugs reached such strong results
- Consider safety and side effects, including what Hy’s Law means and why regulators watch liver signals so closely
- Look ahead to what these medications may mean for NT1, NT2, IH, and other hypersomnolence disorders in the coming years
- Speculate why this class represents one of the most exciting moments in modern sleep medicine
Produced by: Maeve Winter
More
- Twitter: @drchriswinter
- IG: @drchriwinter
- Threads: @drchriswinter
- Bluesky: @drchriswinter
- The Sleep Solution and The Rested Child
Thanks for listening and sleep well!
179 episodes
All episodes
×Welcome to Player FM!
Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.